Secretoglobin family 3A member 2
SCGB3A2proteinSCGB3A2 modulates plaque inflammation and endothelial activation in atherothrombotic lesions during STEMI pathogenesis.
Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleSecreted protein; plaque inflammation and atherosclerosis development via immune modulation.
Also acts inEndothelial activation/erosion
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000164265
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- Lysophospholipids as Predictive Markers of ST-Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI).Metabolites · 2020 · PMID 33396480 · doi